May 12, 2022 / 03:40PM GMT
Leon Wang - BofA Securities, Inc. - Analyst
(audio in progress) joining. My name is Leon Wang, one of Tazeen Ahmad's associate. It is my pleasure to introduce you all to Douglas Love, CEO of Annexon. Doug, pleasure to have you.
Douglas Love - Annexon, Inc. - President & CEO
Thanks for having us. We are really happy to be here this morning.
Questions and Answers:
Leon Wang - BofA Securities, Inc. - AnalystGreat, great. So for those who may not be as familiar with the Annexon story, can you give us an overview of the technology? What's in your pipeline?
Douglas Love - Annexon, Inc. - President & CEO
Yeah, absolutely. So Annexon is focused on complement and specifically, the classical pathway, one of the three components of the complement system.
And what our thesis is that by blocking C1q in the classical pathway, we are providing more complete protection against aberrant complement activity.
So in a nutshell, in indications or diseases
Trustpilot
